Tyra Biosciences Inc
NASDAQ:TYRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Tyra Biosciences Inc
Total Liabilities
Tyra Biosciences Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tyra Biosciences Inc
NASDAQ:TYRA
|
Total Liabilities
$23.4m
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$137.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$36.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$81.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$9.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
Tyra Biosciences Inc
Glance View
Tyra Biosciences, Inc. develops therapies for oncology and cancer diseases. The company is headquartered in Carlsbad, California and currently employs 25 full-time employees. The company went IPO on 2021-09-15. The firm is focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The firm uses its proprietary SNAP platform, which enables refinement of structural design through iterative molecular SNAPshots. The firm is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR), which are altered in approximately 7% of all cancers. Its lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. In addition, it has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase (RET), and FGFR4-related cancers.
See Also
What is Tyra Biosciences Inc's Total Liabilities?
Total Liabilities
23.4m
USD
Based on the financial report for Dec 31, 2025, Tyra Biosciences Inc's Total Liabilities amounts to 23.4m USD.
What is Tyra Biosciences Inc's Total Liabilities growth rate?
Total Liabilities CAGR 3Y
41%
Over the last year, the Total Liabilities growth was 15%. The average annual Total Liabilities growth rates for Tyra Biosciences Inc have been 41% over the past three years .
